Lung cancer
Conditions
Interventions
NA:Percutaneous transluminal single-needle tract biopsy with simultaneous MWA in elderly patients with early-stage lung cancer who meet the inclusion criteria.
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Signed informed consent, age =65 years old; (2) Pathologically confirmed diagnosis of lung cancer, determined to be early stage by PET-CT, enhanced CT and other imaging examinations (AJCC 9th edition stage ?A, ?B, ?A, i.e., tumor diameter =5cm, no lymph nodes and distant metastases); (3) Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-3; (4) Inability to tolerate or refusal of surgery and radiotherapy; (5) Primary patients who, in addition to supportive therapy, did not receive any other adjuvant therapy before residual, recurrent, or metastatic tumor was detected; (6) The treatment process cooperates with the provision of clinicopathological data and imaging data required for the research process, cooperates with the follow-up and collection of blood from the node for clinical efficacy assessment, and agrees to use the test data for the follow-up research.
Exclusion criteria
Exclusion criteria: (1) Severe bleeding and coagulation disorders, platelets less than 50 x 109/L; (2) Eastern Oncology Collaborative Physical Status Score >3; (3) Severe systemic infection, high fever (>38.5°C), skin infection and breakdown at the puncture site; (4) Combination of other malignant tumors; (5) Those with incomplete information or unable to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between blood ctDNA-based MRD and tumor recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| MRD positivity earlier than imaging review, serum tumor markers suggesting recurrence.; | — |
Countries
China
Contacts
Public ContactXiao-guang Li
Beijing Hospital
Outcome results
None listed